Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Drug Makers Step Up R&D To Substitute For Patent Loss

This article was originally published in PharmAsia News

Executive Summary

Japanese drug makers facing patent expiration on some of their blockbuster drugs in the next two to three years are stepping up their research and development to find potential replacements. Takeda Pharmaceutical and Eisai are expected to be hit especially hard in the sales area as they lose patent protection for their top drugs in 2011 and 2010, respectively. Astellas Pharma is an example of the impact of losing that protection. It foresees a 6 percent drop in the sales of its Prograf (tacrolimus) this year as a result of losing its patent on March 31. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts